Why Harvard Bioscience, Inc.’s (HBIO) Stock Is Down 16.10%
As of Friday, February 21, Harvard Bioscience, Inc.’s HBIO share price has dipped by 16.10%, which has investors questioning if this is right time to buy.Aneeqa Nadeem
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Aneeqa Nadeem
Aneeqa Nadeem
Jack Gilleland
Jenna Brashear
Eunice Kim
| Share Statistics | HBIO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $27.5 | $1,790.4 | 12% |
|
| Shares Out (Mil) | 4.5 | 94.8 | 13% |
|
| Institutional Ownership | 79.5% | 90.0% | 49% |
|
| Float (Mil) | 3.5 | 69.9 | 9% |
|
| Beta | 1.57 | 1.20 | 84% |
|
| Avg Daily Volume (000s) | 11 | 814 | 17% |
|
| Price Change (52-week) |
27.9% | 80.2% | 67% |
|
| Growth | HBIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (3.2%) | 7.8% | 11% |
|
| Net Income (5yr) | (48.7%) | (13.7%) | 7% |
|
| EPS (5yr) | (44.7%) | 0.7% | 4 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.210) | ($0.700) | $0.440 | |
| Month Ago EPS | ($0.210) | ($0.700) | $0.440 | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | $0.020 | $0.190 | $0.820 | |
| Year/Year Chg | (72.7%) | (94.5%) | na | |
| Financials | HBIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $86 | $785 | 25% |
|
| Net Income (TTM) (Mil) | ($10) | ($14) | 29% |
|
| EPS (TTM) | ($2.196) | ($0.200) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | $3 | $53 | 35% |
|
| Net Cash Flow (TTM) (Mil) | $2 | ($4) | 48% |
|
| Long-Term Debt (Q1) (Mil) | $43 | $270 | 38% |
|
| Enterprise Value (Q1) (Mil) | $63 | $2,444 | 18% |
|
| Valuation | HBIO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.74 | 2.92 | 62% |
|
| P/E | na | 43.7 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 5.3 | na |
|
| Ratios | HBIO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 58.4% | 47.6% | 71% |
|
| Net Margin | (11.4%) | (2.9%) | 20% |
|
| ROA | (12.4%) | (2.8%) | 24% |
|
| ROE | (78.6%) | (4.5%) | 11% |
|
| Liabilities to Assets | 87.1% | 43.0% | 81% |
|
| F-Score | 6 | 5 | 69% |
|
Harvard Bioscience, Inc. did not pass any screens on 7/31/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors